

# Wenhu Duan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4829940/publications.pdf>

Version: 2024-02-01

30  
papers

648  
citations

567281

15  
h-index

580821

25  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1008  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Bifunctional Sulfonamide Primary Amine-Catalyzed Enantioselective Conjugate Addition of Ketones to Nitroolefins. <i>Advanced Synthesis and Catalysis</i> , 2008, 350, 2194-2198.	4.3	68
2	Discovery of Substituted 1 <i>H</i> -Pyrazolo[3,4- <i>b</i> ]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 629-634.	2.8	58
3	Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6289-6304.	6.4	53
4	Discovery of 3-(5-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1 <i>H</i> -indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6690-6708.	6.4	44
5	Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4 $\beta$ . <i>Theranostics</i> , 2019, 9, 2606-2617.	10.0	40
6	Efficient, Enantioselective Organocatalytic Synthesis of Trichostatin A. <i>Advanced Synthesis and Catalysis</i> , 2006, 348, 1228-1234.	4.3	36
7	Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and <i>in Vivo</i> Antitumor Profiles. <i>Chemical Research in Toxicology</i> , 2018, 31, 1213-1218.	3.3	32
8	Discovery of Anilopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 673-678.	2.8	30
9	Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- <i>b</i> ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2016, 116, 239-251.	5.5	27
10	Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9085-9104.	6.4	25
11	Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8194-8207.	6.4	25
12	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 82-87.	2.8	22
13	Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1 <i>H</i> )-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 317-333.	5.5	19
14	O $\alpha$ -Linked Triazolotriazines: Potent and Selective c-Met Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1276-1285.	3.2	18
15	Design and synthesis of Imidazo[1,2- <i>b</i> ]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112092.	5.5	16
16	DW14006 as a Direct AMPK $\beta$ Activator Ameliorates Diabetic Peripheral Neuropathy in Mice. <i>Diabetes</i> , 2020, 69, 1974-1988.	0.6	15
17	Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. <i>Journal of Computer-Aided Molecular Design</i> , 2019, 33, 775-785.	2.9	14
18	One-Pot Synthesis of Isoindolinones via Three-Component Mannich/Lactamization Cascade Reaction. <i>Synthetic Communications</i> , 2012, 42, 1115-1127.	2.1	13

#	ARTICLE	IF	CITATIONS
19	Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 592-597.	2.8	13
20	DW14006 as a direct AMPK $\alpha$ 1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation. Brain, Behavior, and Immunity, 2020, 90, 55-69.	4.1	13
21	Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2017, 139, 128-152.	5.5	12
22	Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 220, 113497.	5.5	12
23	Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3956-3975.	6.4	9
24	Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. MedChemComm, 2015, 6, 1375-1380.	3.4	7
25	Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2594-2599.	2.2	7
26	Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. Oncotarget, 2016, 7, 38091-38104.	1.8	6
27	Discovery of 1,3-diarylpyridones as Potent VEGFR $\alpha$ 2 Inhibitors: Design, Synthesis, and Biological Evaluation. Chemical Biology and Drug Design, 2016, 87, 694-703.	3.2	5
28	Synthesis and Bioevaluation of Shikonin Derivatives. Letters in Drug Design and Discovery, 2018, 15, 945-950.	0.7	4
29	Synthesis of triazolotriazine derivatives as c-Met inhibitors. Molecular Diversity, 2021, 25, 839-846.	3.9	3
30	Discovery and structure-activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116422.	3.0	1